Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 332

1.

The density and spatial tissue distribution of CD8+ and CD163+ immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors.

Massi D, Rulli E, Cossa M, Valeri B, Rodolfo M, Merelli B, De Logu F, Nassini R, Del Vecchio M, Di Guardo L, De Penni R, Guida M, Sileni VC, Di Giacomo AM, Tucci M, Occelli M, Portelli F, Vallacchi V, Consoli F, Quaglino P, Queirolo P, Baroni G, Carnevale-Schianca F, Cattaneo L, Minisini A, Palmieri G, Rivoltini L, Mandalà M; Italian Melanoma Intergroup.

J Immunother Cancer. 2019 Nov 15;7(1):308. doi: 10.1186/s40425-019-0797-4.

2.

Nevi and Breslow thickness in melanoma: sex differences?

De Giorgi V, Scarfì F, Gori A, Maida P, Trane L, Silvestri F, Portelli F, Massi D, Covarelli P, Gandini S.

Melanoma Res. 2019 Jan 30. doi: 10.1097/CMR.0000000000000579. [Epub ahead of print]

PMID:
31574530
3.

Evaluation of the liquid biopsy for the detection of BRAFV600E mutation in metastatic melanoma patients.

Salvianti F, Massi D, De Giorgi V, Gori A, Pazzagli M, Pinzani P.

Cancer Biomark. 2019;26(3):271-279. doi: 10.3233/CBM-181647.

PMID:
31524142
4.

Machine versus man in skin cancer diagnosis.

Massi D, Laurino M.

Lancet Oncol. 2019 Jul;20(7):891-892. doi: 10.1016/S1470-2045(19)30391-2. Epub 2019 Jun 11. No abstract available.

PMID:
31201138
5.

An updated European Organisation for Research and Treatment of Cancer (EORTC) protocol for pathological evaluation of sentinel lymph nodes for melanoma.

Cook MG, Massi D, Szumera-Ciećkiewicz A, Van den Oord J, Blokx W, van Kempen LC, Balamurugan T, Bosisio F, Koljenović S, Portelli F, van Akkooi ACJ; EORTC Melanoma Group.

Eur J Cancer. 2019 Jun;114:1-7. doi: 10.1016/j.ejca.2019.03.010. Epub 2019 Apr 17.

PMID:
31005015
6.

Image Gallery: In vivo fluorescence-advanced videodermatoscopy for the characterization of skin melanocytic pigmented lesions.

Scarfì F, Gori A, Topa A, Trane L, Dika E, Broganelli P, Massi D, De Giorgi V.

Br J Dermatol. 2019 Apr;180(4):e104. doi: 10.1111/bjd.17457. No abstract available.

PMID:
30933350
7.

Cutaneous leiomyosarcoma: a clinical, dermoscopic, pathologic case study.

De Giorgi V, Scarfì F, Silvestri F, Maida P, Gori A, Trane L, Massi D.

Exp Oncol. 2019 Mar;41(1):80-81.

PMID:
30932400
8.

MC1R variants in childhood and adolescent melanoma: a retrospective pooled analysis of a multicentre cohort.

Pellegrini C, Botta F, Massi D, Martorelli C, Facchetti F, Gandini S, Maisonneuve P, Avril MF, Demenais F, Bressac-de Paillerets B, Hoiom V, Cust AE, Anton-Culver H, Gruber SB, Gallagher RP, Marrett L, Zanetti R, Dwyer T, Thomas NE, Begg CB, Berwick M, Puig S, Potrony M, Nagore E, Ghiorzo P, Menin C, Manganoni AM, Rodolfo M, Brugnara S, Passoni E, Sekulovic LK, Baldini F, Guida G, Stratigos A, Ozdemir F, Ayala F, Fernandez-de-Misa R, Quaglino P, Ribas G, Romanini A, Migliano E, Stanganelli I, Kanetsky PA, Pizzichetta MA, García-Borrón JC, Nan H, Landi MT, Little J, Newton-Bishop J, Sera F, Fargnoli MC, Raimondi S; IMI Study Group; GEM Study Group; M-SKIP Study Group.

Lancet Child Adolesc Health. 2019 May;3(5):332-342. doi: 10.1016/S2352-4642(19)30005-7. Epub 2019 Mar 12.

PMID:
30872112
9.

Fluorescence-advanced videodermatoscopy: A promising and potential technique for the in vivo evaluation of vitiligo.

Scarfì F, Gori A, Silvestri F, Trane L, Portelli F, Maida P, Dika E, Broganelli P, Massi D, De Giorgi V.

Dermatol Ther. 2019 May;32(3):e12863. doi: 10.1111/dth.12863. Epub 2019 Mar 18.

PMID:
30767395
10.

Cutaneous eruptions associated with haematologic malignancies: the need for a unifying nomenclature.

Maglie R, Grandi V, Massi D, Caproni M, Pimpinelli N, Antiga E.

J Eur Acad Dermatol Venereol. 2019 May;33(5):e191-e192. doi: 10.1111/jdv.15452. Epub 2019 Feb 28. No abstract available.

PMID:
30697822
11.

Melanoma types by in vivo reflectance confocal microscopy correlated with protein and molecular genetic alterations: A pilot study.

Beretti F, Bertoni L, Farnetani F, Pellegrini C, Gorelli G, Cesinaro AM, Reggiani Bonetti L, Di Nardo L, Kaleci S, Chester J, Longo C, Massi D, Fargnoli MC, Pellacani G.

Exp Dermatol. 2019 Mar;28(3):254-260. doi: 10.1111/exd.13877. Epub 2019 Feb 11.

PMID:
30636079
12.

Primary Orbital Synovial Sarcoma Mimicking a Periocular Cyst.

Portelli F, Pieretti G, Santoro N, Gorelli G, De Giorgi V, Massi D, Dei Tos AP, Mazzini C.

Am J Dermatopathol. 2019 Sep;41(9):655-660. doi: 10.1097/DAD.0000000000001351.

PMID:
30624245
13.

Eosinophilic dermatosis of hematologic malignancy: A retrospective cohort of 37 patients from an Italian center.

Grandi V, Maglie R, Antiga E, Vannucchi M, Delfino C, Lastrucci I, Gunnella S, Ciolli S, Quintarelli L, Massi D, Caproni M, Pimpinelli N.

J Am Acad Dermatol. 2019 Jul;81(1):246-249. doi: 10.1016/j.jaad.2018.11.048. Epub 2018 Dec 5. No abstract available.

PMID:
30528498
14.

Prognostic impact of regression in patients with primary cutaneous melanoma >1 mm in thickness.

Ribero S, Galli F, Osella-Abate S, Bertero L, Cattaneo L, Merelli B, Tondini C, Ghilardi L, De Giorgi V, Occelli M, Quaglino P, Cassoni P, Palmieri G, Massi D, Mandala M; Italian Melanoma Intergroup.

J Am Acad Dermatol. 2019 Jan;80(1):99-105.e5. doi: 10.1016/j.jaad.2018.06.054. Epub 2018 Nov 14.

PMID:
30447951
15.

A Critical Reappraisal of Primary and Recurrent Advanced Laryngeal Cancer Staging.

Locatello LG, Pietragalla M, Taverna C, Bonasera L, Massi D, Mannelli G.

Ann Otol Rhinol Laryngol. 2019 Jan;128(1):36-43. doi: 10.1177/0003489418806915. Epub 2018 Oct 26.

PMID:
30360641
16.

The burden of cutaneous adnexal carcinomas and the risk of associated squamous cell carcinoma: a population-based study.

De Giorgi V, Salvati L, Barchielli A, Caldarella A, Gori A, Scarfì F, Savarese I, Pimpinelli N, Urso C, Massi D.

Br J Dermatol. 2019 Mar;180(3):565-573. doi: 10.1111/bjd.17321. Epub 2018 Dec 26.

PMID:
30328107
17.

MelaNostrum: a consensus questionnaire of standardized epidemiologic and clinical variables for melanoma risk assessment by the melanostrum consortium.

Stratigos AJ, Fargnoli MC, De Nicolo A, Peris K, Puig S, Soura E, Menin C, Calista D, Ghiorzo P, Mandala M, Massi D, Rodolfo M, Del Regno L, Stefanaki I, Gogas H, Bataille V, Tucker MA, Whiteman D, Nagore E, Landi MT.

J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2134-2141. doi: 10.1111/jdv.15208. Epub 2018 Sep 14.

PMID:
30098061
18.

Clinical and Dermoscopic Features of Lichenoid Keratosis: A Retrospective Case Study.

Gori A, Oranges T, Janowska A, Savarese I, Chiarugi A, Nardini P, Salvati L, Maria Palleschi G, Scarfì F, Massi D, Innocenti A, Covarelli P, De Giorgi V.

J Cutan Med Surg. 2018 Nov/Dec;22(6):561-566. doi: 10.1177/1203475418786213. Epub 2018 Jul 18.

PMID:
30016886
19.

Improved label-free diagnostics and pathological assessment of atherosclerotic plaques through nonlinear microscopy.

Baria E, Nesi G, Santi R, Maio V, Massi D, Pratesi C, Cicchi R, Pavone FS.

J Biophotonics. 2018 Nov;11(11):e201800106. doi: 10.1002/jbio.201800106. Epub 2018 Jul 13.

PMID:
29931805
20.

At the Root: Cutaneous Langerhans Cell Histiocytosis.

Maglie R, Vannucchi M, Quintarelli L, Caproni M, Massi D, Antiga E.

Am J Med. 2018 Aug;131(8):922-926. doi: 10.1016/j.amjmed.2018.04.015. Epub 2018 May 2. No abstract available.

PMID:
29729245
21.

Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) is a novel marker for patients with BRAF-mutated metastatic melanoma.

Audrito V, Managò A, Zamporlini F, Rulli E, Gaudino F, Madonna G, D'Atri S, Antonini Cappellini GC, Ascierto PA, Massi D, Raffaelli N, Mandalà M, Deaglio S.

Oncotarget. 2018 Apr 10;9(27):18997-19005. doi: 10.18632/oncotarget.24871. eCollection 2018 Apr 10.

22.

Correction to: Clinicopathological predictors of recurrence in nodular and superficial spreading cutaneous melanoma: a multivariate analysis of 214 cases.

Pizzichetta MA, Massi D, Mandalà M, Queirolo P, Stanganelli I, De Giorgi V, Ghigliotti G, Cavicchini S, Quaglino P, Corradin MT, Rubegni P, Alaibac M, Astorino S, Ayala F, Magi S, Mazzoni L, Manganoni MA, Talamini R, Serraino D, Palmieri G; Italian Melanoma Intergroup (IMI).

J Transl Med. 2018 Feb 20;16(1):33. doi: 10.1186/s12967-018-1408-8.

23.

ECCO essential requirements for quality cancer care: Melanoma.

Wouters MW, Michielin O, Bastiaannet E, Beishon M, Catalano O, Del Marmol V, Delgado-Bolton R, Dendale R, Trill MD, Ferrari A, Forsea AM, Kreckel H, Lövey J, Luyten G, Massi D, Mohr P, Oberst S, Pereira P, Prata JPP, Rutkowski P, Saarto T, Sheth S, Spurrier-Bernard G, Vuoristo MS, Costa A, Naredi P.

Crit Rev Oncol Hematol. 2018 Feb;122:164-178. doi: 10.1016/j.critrevonc.2017.12.020. Epub 2018 Jan 2. Review.

24.

Venous outlet syndrome caused by capillary hemangioma of the subclavian vein.

Bongiolatti S, Massi D, Maio V, Gonfiotti A, Viggiano D, Voltolini L.

Asian Cardiovasc Thorac Ann. 2018 Mar;26(3):224-226. doi: 10.1177/0218492318760693. Epub 2018 Feb 14.

PMID:
29444598
25.

Nicotinamide Phosphoribosyltransferase (NAMPT) as a Therapeutic Target in BRAF-Mutated Metastatic Melanoma.

Audrito V, Managò A, La Vecchia S, Zamporlini F, Vitale N, Baroni G, Cignetto S, Serra S, Bologna C, Stingi A, Arruga F, Vaisitti T, Massi D, Mandalà M, Raffaelli N, Deaglio S.

J Natl Cancer Inst. 2018 Mar 1;110(3). doi: 10.1093/jnci/djx198.

PMID:
29309612
26.

Clinicopathological predictors of recurrence in nodular and superficial spreading cutaneous melanoma: a multivariate analysis of 214 cases.

Pizzichetta MA, Massi D, Mandalà M, Queirolo P, Stanganelli I, De Giorgi V, Ghigliotti G, Cavicchini S, Quaglino P, Corradin MT, Rubegni P, Alaibac M, Astorino S, Ayala F, Magi S, Mazzoni L, Manganoni MA, Talamini R, Serraino D, Palmieri G; Italian Melanoma Intergroup (IMI).

J Transl Med. 2017 Nov 7;15(1):227. doi: 10.1186/s12967-017-1332-3. Erratum in: J Transl Med. 2018 Feb 20;16(1):33.

27.

Bullous eruption in a patient with B-cell chronic lymphocytic leukemia: a diagnostic challenge.

Maglie R, Antiga E, Vannucchi M, Del Bianco E, Bianchi B, Massi D, Caproni M.

Int J Dermatol. 2017 Dec;56(12):1445-1447. doi: 10.1111/ijd.13807. Epub 2017 Oct 26. No abstract available.

PMID:
29076242
28.

mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition.

Xue G, Kohler R, Tang F, Hynx D, Wang Y, Orso F, Prêtre V, Ritschard R, Hirschmann P, Cron P, Roloff T, Dummer R, Mandalà M, Bichet S, Genoud C, Meyer AG, Muraro MG, Spagnoli GC, Taverna D, Rüegg C, Merghoub T, Massi D, Tang H, Levesque MP, Dirnhofer S, Zippelius A, Hemmings BA, Wicki A.

Oncotarget. 2017 May 25;8(41):69204-69218. doi: 10.18632/oncotarget.18213. eCollection 2017 Sep 19.

29.

Steroid treatment of acute graft-versus-host disease grade I: a randomized trial.

Bacigalupo A, Milone G, Cupri A, Severino A, Fagioli F, Berger M, Santarone S, Chiusolo P, Sica S, Mammoliti S, Sorasio R, Massi D, Van Lint MT, Raiola AM, Gualandi F, Selleri C, Sormani MP, Signori A, Risitano A, Bonifazi F; Gruppo Italiano Trapianto di Midollo Osseo (GITMO).

Haematologica. 2017 Dec;102(12):2125-2133. doi: 10.3324/haematol.2017.171157. Epub 2017 Sep 29.

30.

Lichen planus triggered by CT-P13 and recurrence during secukinumab treatment.

Maglie R, Di Cesare A, Lazzeri L, Pescitelli L, Ricceri F, Vannucchi M, Massi D, Prignano F.

Br J Dermatol. 2018 Jan;178(1):303-304. doi: 10.1111/bjd.16003. Epub 2017 Dec 29. No abstract available.

PMID:
28940185
31.

Post-ivermectin encephalopathy in Senegal: a case report.

Massi DG, Mansare ML, Traoré M, Ndiaye M, Diop AG, Ndiaye MM.

Pan Afr Med J. 2017 Jul 18;27:202. doi: 10.11604/pamj.2017.27.202.12106. eCollection 2017.

32.

Species distribution models of two critically endangered deep-sea octocorals reveal fishing impacts on vulnerable marine ecosystems in central Mediterranean Sea.

Lauria V, Garofalo G, Fiorentino F, Massi D, Milisenda G, Piraino S, Russo T, Gristina M.

Sci Rep. 2017 Aug 14;7(1):8049. doi: 10.1038/s41598-017-08386-z.

33.

New insights into naevoid melanomas: a clinicopathological reassessment.

Cook MG, Massi D, Blokx WAM, Van den Oord J, Koljenović S, De Giorgi V, Kissin E, Grant M, Mandal A, Gremel G, Gaudy C, Viros A, Dhomen N, Khosrotehrani K, Marais R, Green AC, Mihm MC Jr.

Histopathology. 2017 Dec;71(6):943-950. doi: 10.1111/his.13317. Epub 2017 Oct 2.

PMID:
28741688
34.

PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux.

O'Donnell JS, Massi D, Teng MWL, Mandala M.

Semin Cancer Biol. 2018 Feb;48:91-103. doi: 10.1016/j.semcancer.2017.04.015. Epub 2017 May 2. Review.

PMID:
28467889
35.

Rationale for New Checkpoint Inhibitor Combinations in Melanoma Therapy.

Mandalà M, Tondini C, Merelli B, Massi D.

Am J Clin Dermatol. 2017 Oct;18(5):597-611. doi: 10.1007/s40257-017-0282-0. Review.

PMID:
28432648
36.

Kaposi sarcoma in a patient treated with ruxolitinib.

Loscocco GG, Vannucchi M, Paoli C, Franci A, Pieri L, Annunziato F, Massi D, Vannucchi AM.

Ann Oncol. 2017 Jul 1;28(7):1670-1671. doi: 10.1093/annonc/mdx188. No abstract available.

37.

Droplet digital PCR (ddPCR) vs quantitative real-time PCR (qPCR) approach for detection and quantification of Merkel cell polyomavirus (MCPyV) DNA in formalin fixed paraffin embedded (FFPE) cutaneous biopsies.

Arvia R, Sollai M, Pierucci F, Urso C, Massi D, Zakrzewska K.

J Virol Methods. 2017 Aug;246:15-20. doi: 10.1016/j.jviromet.2017.04.003. Epub 2017 Apr 14.

PMID:
28414163
38.

Baseline β-catenin, programmed death-ligand 1 expression and tumour-infiltrating lymphocytes predict response and poor prognosis in BRAF inhibitor-treated melanoma patients.

Massi D, Romano E, Rulli E, Merelli B, Nassini R, De Logu F, Bieche I, Baroni G, Cattaneo L, Xue G, Mandalà M.

Eur J Cancer. 2017 Jun;78:70-81. doi: 10.1016/j.ejca.2017.03.012. Epub 2017 Apr 14.

PMID:
28412591
39.

Sister Mary Joseph node.

Prignano F, Lazzeri L, Massi D.

QJM. 2017 Jul 1;110(7):473. doi: 10.1093/qjmed/hcx075. No abstract available.

PMID:
28398511
40.

Superior Foville syndrome due to pontine hemorrhage: a case report.

Massi DG, Nyassinde J, Ndiaye MM.

Pan Afr Med J. 2016 Dec 6;25:215. doi: 10.11604/pamj.2016.25.215.10648. eCollection 2016.

41.

Role of BMI and hormone therapy in melanoma risk: a case-control study.

De Giorgi V, Gori A, Savarese I, D'Errico A, Scarfì F, Papi F, Maio V, Covarelli P, Massi D, Gandini S.

J Cancer Res Clin Oncol. 2017 Jul;143(7):1191-1197. doi: 10.1007/s00432-017-2387-5. Epub 2017 Mar 13.

PMID:
28289899
42.

Clinical and dermoscopic features of truly amelanotic plantar melanoma.

De Giorgi V, Gori A, Savarese I, D'Errico A, Papi F, Grazzini M, Scarfì F, Covarelli P, Massi D.

Melanoma Res. 2017 Jun;27(3):224-230. doi: 10.1097/CMR.0000000000000337.

PMID:
28252554
43.

Immunotolerance as a Mechanism of Resistance to Targeted Therapies in Melanoma.

Mandalà M, Massi D.

Handb Exp Pharmacol. 2018;249:129-143. doi: 10.1007/164_2017_5.

PMID:
28238077
44.

PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p.

Audrito V, Serra S, Stingi A, Orso F, Gaudino F, Bologna C, Neri F, Garaffo G, Nassini R, Baroni G, Rulli E, Massi D, Oliviero S, Piva R, Taverna D, Mandalà M, Deaglio S.

Oncotarget. 2017 Feb 28;8(9):15894-15911. doi: 10.18632/oncotarget.15213.

45.

Virchows Archiv-an update, and plans for the future.

Massi D.

Virchows Arch. 2017 Jan;470(1):3-4. doi: 10.1007/s00428-016-2059-x. No abstract available.

PMID:
28012069
46.

Immunomodulating property of MAPK inhibitors: from translational knowledge to clinical implementation.

Mandalà M, De Logu F, Merelli B, Nassini R, Massi D.

Lab Invest. 2017 Feb;97(2):166-175. doi: 10.1038/labinvest.2016.132. Epub 2016 Dec 19. Review.

47.

Mitotic rate correlates with sentinel lymph node status and outcome in cutaneous melanoma greater than 1 millimeter in thickness: A multi-institutional study of 1524 cases.

Mandalà M, Galli F, Cattaneo L, Merelli B, Rulli E, Ribero S, Quaglino P, De Giorgi V, Pigozzo J, Sileni VC, Chirco A, Ferrucci PF, Occelli M, Imberti G, Piazzalunga D, Massi D, Tondini C, Queirolo P; Italian Melanoma Intergroup.

J Am Acad Dermatol. 2017 Feb;76(2):264-273.e2. doi: 10.1016/j.jaad.2016.08.066. Epub 2016 Nov 12.

PMID:
27847125
48.

AKT-ions with a TWIST between EMT and MET.

Tang H, Massi D, Hemmings BA, Mandalà M, Hu Z, Wicki A, Xue G.

Oncotarget. 2016 Sep 20;7(38):62767-62777. doi: 10.18632/oncotarget.11232. Review.

49.

PD-L1 in melanoma: facts and myths.

Mandalà M, Merelli B, Massi D.

Melanoma Manag. 2016 Sep;3(3):187-194. doi: 10.2217/mmt-2016-0013. Epub 2016 Aug 22. Review.

50.

Estrogen receptor (ER)β expression and worse outcome from melanoma in pregnant and perimenopausal women.

Gori A, Savarese I, D'Errico A, Grazzini M, Papi F, Maio V, Covarelli P, Massi D, Gandini S, De Giorgi V.

J Am Acad Dermatol. 2016 Sep;75(3):e117. doi: 10.1016/j.jaad.2016.02.1245. No abstract available.

PMID:
27543235

Supplemental Content

Support Center